Global leader in gene therapyHelixmith
Helixmith has been devoted to gene therapy research
since its establishment in 1996, leading innovation through
next-generation gene therapy products.
Leading Pipeline of HelixmithEngensis (VM202)
VM202 is a plasmid DNA treatment designed to simultaneosly
express two isoforms (HGF728, HGF723) of the protein
hepatocayte growth factor (HGF).
Global leader in gene therapy,Helixmith
Global leader in DNA gene therapy development;
Taking the lead in development of gene theraphy
treatment in the cardiovascular disease indication.